Probiodrug Gets €36M for Novel Alzheimer's Program
BioWorld Today Correspondent
In what could well be Europe's largest venture capital investment in biotechnology this year, Probiodrug AG took in more than €36 million (US$53.4 million) in a Series B round to fund a new class of Alzheimer's disease drugs, based on inhibiting glutaminyl cyclase (QC). The company also will allocate part of the proceeds to developing compounds acting on the same target for treating inflammatory indications.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST